HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Friday morning, Benzinga reports. HC Wainwright currently has a $50.00 price target on the stock.

GMAB has been the subject of several other reports. Truist Financial lifted their target price on Genmab A/S from $50.00 to $53.00 and gave the stock a buy rating in a research note on Tuesday, June 4th. BTIG Research lifted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a buy rating in a research report on Thursday, June 27th. Finally, Royal Bank of Canada upgraded shares of Genmab A/S from a sector perform rating to an outperform rating in a report on Monday, July 15th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and an average price target of $49.50.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $26.51 on Friday. Genmab A/S has a 52-week low of $24.53 and a 52-week high of $39.53. The company has a market capitalization of $17.53 billion, a P/E ratio of 22.09, a price-to-earnings-growth ratio of 1.01 and a beta of 0.97. The company has a 50-day simple moving average of $26.74 and a 200 day simple moving average of $28.21.

Institutional Trading of Genmab A/S

A number of institutional investors have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. raised its position in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of Genmab A/S by 26.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after acquiring an additional 45,376 shares during the period. Headlands Technologies LLC grew its holdings in shares of Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares in the last quarter. Finally, Choreo LLC acquired a new stake in shares of Genmab A/S during the 2nd quarter worth $776,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.